Epithelial Ovarian Cancer (EOC) is a common and often deadly disease among women, with High-Grade Serous Ovarian Carcinoma (HGSOC) making up about 75% of cases. Standard treatment includes surgery and platinum-based chemotherapy. Recent studies highlight the effectiveness of Poly (ADP-Ribose) Polymerase (PARP) inhibitors, especially for patients with BRCA1/2 mutations or Homologous Recombination Deficiency (HRD). HRD status is a key biomarker for predicting PARP inhibitor success, even without BRCA mutations. Genomic signatures can detect HRD independently. Healthcare professionals assess HRD by evaluating genomic instability and recommend PARP inhibitors for patients with an HRD score of 42 or higher. Combination maintenance therapy with Olaparib and Bevacizumab has shown improved survival for HRD-positive or BRCA-mutated patients. A case report of a 36-year-old woman with advanced ovarian cancer showed a positive treatment response and tumor-free lymph nodes after neoadjuvant chemotherapy, surgery, and targeted therapy. Combination maintenance therapy with a PARP inhibitor and Bevacizumab is crucial in advanced ovarian cancer treatment.
In conclusion, a combination of a PARP inhibitor and bevacizumab for maintenance therapy is essential in the treatment of advanced ovarian cancer. Patients in stages 3 and 4 gain significant benefits from this approach, which is customized according to their initial treatment, BRCA mutation status, and Homologous Recombination Deficiency (HRD) status.